Higher Frequency of NK and CD4+ T-Cells in Mucosa and Potent Cytotoxic Response in HIV Controllers

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Aug 21

PMID 26291824

Citations 14

Authors

Natalia Andrea Taborda

Sandra Milena Gonzalez

Cristiam Mauricio Alvarez

Luis Alfonso Correa

Carlos Julio Montoya

Maria Teresa Rugeles

Affiliations

Soon will be listed here.

Abstract

HIV infection induces immune alterations, mainly in gut mucosa, where the main target cells reside. However, the evolution of the infection is variable among infected individuals, as evidenced by HIV controllers who exhibit low or undetectable viral load in the absence of treatment. The aim of this study was to evaluate the frequency, phenotype and activity of T and NK cells in peripheral blood and gut mucosa in a cohort of Colombian HIV controllers. Blood and gut biopsies were included. The frequency and the activation status of T and NK cells were performed by flow cytometry. In addition, Gag-stimulated CD8+ T-cells and cytokine-stimulated NK cells were tested for cytotoxic activity. Finally, microbial translocation was measured by plasma lipopolysaccharide quantification. Compared with HIV-progressors, HIV controllers exhibited higher frequency of CD4+ T and NK cells, and lower expression of activation molecules in blood and mucosal immune cells, as well as lower microbial translocation. An increased production of molecules associated with cytotoxic activity of CD8+ T-cells in blood and mucosa and a higher percentage of polyfunctional CD8+ T cells in blood were also observed in HIV controllers. In addition, an increased activity of NK cells was observed in blood. These findings suggest that HIV controllers have a potent immune response, mainly mediated by cytotoxic cells that control HIV replication, which contribute to reducing alterations at the gut mucosa.

Citing Articles

HIV controllers: hope for a functional cure.

Deng Z, Yan H, Lambotte O, Moog C, Su B Front Immunol. 2025; 16:1540932.

PMID: 40070826 PMC: 11893560. DOI: 10.3389/fimmu.2025.1540932.

Plasma metabolomics by nuclear magnetic resonance reveals biomarkers and metabolic pathways associated with the control of HIV-1 infection/progression.

Gomez-Archila L, Palomino-Schatzlein M, Zapata-Builes W, Rugeles M, Galeano E Front Mol Biosci. 2023; 10:1204273.

PMID: 37457832 PMC: 10339029. DOI: 10.3389/fmolb.2023.1204273.

Editorial: Innate immune responses in HIV controllers.

Thobakgale C, Jost S Front Immunol. 2023; 14:1159278.

PMID: 36875132 PMC: 9975703. DOI: 10.3389/fimmu.2023.1159278.

Gut Innate Immunity and HIV Pathogenesis.

Dillon S, Wilson C Curr HIV/AIDS Rep. 2021; 18(2):128-138.

PMID: 33687703 PMC: 10472818. DOI: 10.1007/s11904-021-00544-3.

Identification of SARS-CoV-2-specific immune alterations in acutely ill patients.

Rebillard R, Charabati M, Grasmuck C, Filali-Mouhim A, Tastet O, Brassard N J Clin Invest. 2021; 131(8).

PMID: 33635833 PMC: 8262478. DOI: 10.1172/JCI145853.

References

Turk G, Ghiglione Y, Falivene J, Socias M, Laufer N, Coloccini R . Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ T-cell compartment. J Virol. 2013; 87(13):7445-62. PMC: 3700299. DOI: 10.1128/JVI.00865-13. View

Belyakov I, Ahlers J . Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development. Curr Top Microbiol Immunol. 2011; 354:157-79. DOI: 10.1007/82_2010_119. View

Taborda N, Gonzalez S, Correa L, Montoya C, Rugeles M . Spontaneous HIV Controllers Exhibit Preserved Immune Parameters in Peripheral Blood and Gastrointestinal Mucosa. J Acquir Immune Defic Syndr. 2015; 70(2):115-21. DOI: 10.1097/QAI.0000000000000729. View

Kelleher A, Long C, Holmes E, Allen R, Wilson J, Conlon C . Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med. 2001; 193(3):375-86. PMC: 2195921. DOI: 10.1084/jem.193.3.375. View

Jaspan H, Richard Gaumer H, Garry R . Expression of granzyme B mRNA is altered in human immunodeficiency virus infected patients. Exp Mol Pathol. 2003; 74(1):13-6. DOI: 10.1016/s0014-4800(03)80003-5. View

Kottilil S, Chun T, Moir S, Liu S, McLaughlin M, Hallahan C . Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis. 2003; 187(7):1038-45. DOI: 10.1086/368222. View

Lord S, Rajotte R, Korbutt G, Bleackley R . Granzyme B: a natural born killer. Immunol Rev. 2003; 193:31-8. DOI: 10.1034/j.1600-065x.2003.00044.x. View

Hazenberg M, Otto S, van Benthem B, Roos M, Coutinho R, Lange J . Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003; 17(13):1881-8. DOI: 10.1097/00002030-200309050-00006. View

Mehandru S, Poles M, Tenner-Racz K, Horowitz A, Hurley A, Hogan C . Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004; 200(6):761-70. PMC: 2211967. DOI: 10.1084/jem.20041196. View

10.

Brenchley J, Schacker T, Ruff L, Price D, Taylor J, Beilman G . CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004; 200(6):749-59. PMC: 2211962. DOI: 10.1084/jem.20040874. View

11.

Hendel H, Cho Y, Gauthier N, Rappaport J, Schachter F, Zagury J . Contribution of cohort studies in understanding HIV pathogenesis: introduction of the GRIV cohort and preliminary results. Biomed Pharmacother. 1996; 50(10):480-7. DOI: 10.1016/s0753-3322(97)89278-5. View

12.

Yang O, Lin H, Dagarag M, Ng H, Effros R, Uittenbogaart C . Decreased perforin and granzyme B expression in senescent HIV-1-specific cytotoxic T lymphocytes. Virology. 2005; 332(1):16-9. DOI: 10.1016/j.virol.2004.11.028. View

13.

Sankaran S, Guadalupe M, Reay E, George M, Flamm J, Prindiville T . Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A. 2005; 102(28):9860-5. PMC: 1159164. DOI: 10.1073/pnas.0503463102. View

14.

Kottilil S, Shin K, Jackson J, Reitano K, OShea M, Yang J . Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol. 2006; 176(2):1107-14. DOI: 10.4049/jimmunol.176.2.1107. View

15.

Brenchley J, Price D, Douek D . HIV disease: fallout from a mucosal catastrophe?. Nat Immunol. 2006; 7(3):235-9. DOI: 10.1038/ni1316. View

16.

Betts M, Nason M, West S, De Rosa S, Migueles S, Abraham J . HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006; 107(12):4781-9. PMC: 1895811. DOI: 10.1182/blood-2005-12-4818. View

17.

Potter S, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M . Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol. 2007; 81(24):13904-15. PMC: 2168869. DOI: 10.1128/JVI.01401-07. View

18.

Mela C, Steel A, Lindsay J, Gazzard B, Gotch F, Goodier M . Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals. AIDS. 2007; 21(16):2177-82. DOI: 10.1097/QAD.0b013e3282f08b72. View

19.

Duvall M, Precopio M, Ambrozak D, Jaye A, McMichael A, Whittle H . Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol. 2008; 38(2):350-63. PMC: 2362391. DOI: 10.1002/eji.200737768. View

20.

Pereyra F, Addo M, Kaufmann D, Liu Y, Miura T, Rathod A . Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008; 197(4):563-71. DOI: 10.1086/526786. View